Alnylam Reports Positive Phase 2 Results In Patisiran Study
April 21, 2015 at 21:45 PM EDT
Alnylam shares are up about 2% on the news that Patisiran showed substantial efficacy in the phase 2 OLE study
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.